J&J and Pfizer Lead AQR Capital’s Largest Healthcare Holdings

Wall St. Watchdog reveals information regarding AQR Capital’s top holdings in the Healthcare sector for the quarter ending September 30th, 2011. The firm held 218 stocks in the Healthcare sector at the end of the quarter with an aggregate market value of $1.347 billion.

Johnson & Johnson (NYSE:JNJ): On 06/30/2011, AQR Capital reported holding 1,594,986 shares with a market value of $106,098,463. This comprised 0.78% of the total portfolio. On 09/30/2011, AQR Capital reported holding 1,681,016 shares with a market value of $107,063,907. This comprised 0.87% of the total portfolio. The net change in shares for this position over the two quarters is 86,030. About Company: Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.

Pfizer Inc. (NYSE:PFE): On 06/30/2011, AQR Capital reported holding 3,188,699 shares with a market value of $65,687,201. This comprised 0.48% of the total portfolio. On 09/30/2011, AQR Capital reported holding 4,629,406 shares with a market value of $81,847,899. This comprised 0.66% of the total portfolio. The net change in shares for this position over the two quarters is 1,440,707. About Company: Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company’s products include prescription pharmaceuticals, non-prescription self-medications, and animal health products such as anti-infective medicines and vaccines.

Amgen Inc. (NASDAQ:AMGN): On 06/30/2011, AQR Capital reported holding 1,112,518 shares with a market value of $64,915,424. This comprised 0.48% of the total portfolio. On 09/30/2011, AQR Capital reported holding 1,260,483 shares with a market value of $69,276,145. This comprised 0.56% of the total portfolio. The net change in shares for this position over the two quarters is 147,965. About Company: Amgen Inc. discovers, develops, manufactures, and markets human therapeutics based on cellular and molecular biology. The Company focuses its research on secreted protein and small molecule therapeutics, with particular emphasis on neuroscience and cancer. Amgen concentrates on the areas of hematology, cancer, infectious disease, endocrinology, neurobiology, and inflammation.

Wellpoint Inc. (NYSE:WLP): On 06/30/2011, AQR Capital reported holding 792,102 shares with a market value of $62,393,872. This comprised 0.46% of the total portfolio. On 09/30/2011, AQR Capital reported holding 918,569 shares with a market value of $59,964,183. This comprised 0.49% of the total portfolio. The net change in shares for this position over the two quarters is 126,467. About Company: WellPoint Inc. is a health benefits company. The Company provides health benefits, dental and vision benefits, pharmacy benefits, life insurance, and life and disability insurance benefits. WellPoint operations include Blue Cross and Blue Shield plans.

Humana Inc. (NYSE:HUM): On 06/30/2011, AQR Capital reported holding 781,919 shares with a market value of $62,975,757. This comprised 0.46% of the total portfolio. On 09/30/2011, AQR Capital reported holding 815,501 shares with a market value of $59,311,390. This comprised 0.48% of the total portfolio. The net change in shares for this position over the two quarters is 33,582. About Company: Humana Inc. is a managed health care company with medical members located in the United States and Puerto Rico. The Company offers coordinated health care through health maintenance organizations, preferred provider organizations, point-of-service plans, and administrative services products. Humana offers its products to employer groups, government-sponsored plans, and individuals.

Cephalon Inc. (NASDAQ:CEPH): On 06/30/2011, AQR Capital reported holding 531,370 shares with a market value of $42,456,464. This comprised 0.31% of the total portfolio. On 09/30/2011, AQR Capital reported holding 644,038 shares with a market value of $51,973,865. This comprised 0.42% of the total portfolio. The net change in shares for this position over the two quarters is 112,668. About Company: Cephalon, Inc. is an international biopharmaceutical company that discovers, develops, and markets biopharmaceutical products to treat neurological disorders, pain, and cancer. The Company’s products include a product that treats excessive daytime sleepiness associated with narcolepsy.

Merck & Co. Inc. (NYSE:MRK): On 06/30/2011, AQR Capital reported holding 902,399 shares with a market value of $31,845,662. This comprised 0.23% of the total portfolio. On 09/30/2011, AQR Capital reported holding 1,514,392 shares with a market value of $49,520,620. This comprised 0.4% of the total portfolio. The net change in shares for this position over the two quarters is 611,993. About Company: Merck & Co., Inc. is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of human and animal health products. Merck’s products include a treatment for elevated cholesterol, a treatment for male pattern hair loss, a preventive treatment for osteoporosis, a treatment for hypertension, and a treatment for allergic rhinitis.

Biogen Idec Inc. (NASDAQ:BIIB): On 06/30/2011, AQR Capital reported holding 529,932 shares with a market value of $56,660,328. This comprised 0.42% of the total portfolio. On 09/30/2011, AQR Capital reported holding 520,455 shares with a market value of $48,480,384. This comprised 0.39% of the total portfolio. The net change in shares for this position over the two quarters is -9,477. About Company: Biogen Idec Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company’s products addresses diseases such as multiple sclerosis, non-Hodgkin’s lymphoma, rheumatoid arthritis, crohn’s disease, and psoriasis.

Abbott Laboratories (NYSE:ABT): On 06/30/2011, AQR Capital reported holding 353,916 shares with a market value of $18,623,060. This comprised 0.14% of the total portfolio. On 09/30/2011, AQR Capital reported holding 820,658 shares with a market value of $41,968,450. This comprised 0.34% of the total portfolio. The net change in shares for this position over the two quarters is 466,742. About Company: Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company’s products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.

Hill-rom Holdings Inc. (NYSE:HRC): On 06/30/2011, AQR Capital reported holding 480,528 shares with a market value of $22,123,510. This comprised 0.16% of the total portfolio. On 09/30/2011, AQR Capital reported holding 1,390,728 shares with a market value of $41,749,655. This comprised 0.34% of the total portfolio. The net change in shares for this position over the two quarters is 910,200. About Company: Hill-Rom Holdings, Inc. manufactures equipment for the healthcare industry, and provides wound care and pulmonary/trauma management services. The Company produces hospital beds, mattresses, stretchers, furniture and hospital information technology systems; and offers wound, circulatory and pulmonary therapies.

(Note: Data regarding AQR Capital’s stock holdings are sourced from whalewisdom.com. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>

More from The Cheat Sheet